| Literature DB >> 16542437 |
Michael Pedersen1, Thomas L Benfield, Peter Skinhoej, Allan G Jensen.
Abstract
BACKGROUND: Haematogenous Staphylococcus aureus meningitis is rare but associated with high mortality. Knowledge about the disease is still limited. The objective of this study was to evaluate demographic and clinical prognostic features of bacteraemic S. aureus meningitis.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16542437 PMCID: PMC1421412 DOI: 10.1186/1471-2334-6-49
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Demographic and Laboratory Characteristics of Patients with S. aureus meningitis according to survival.
| Chraracteristics | All Patients (N = 96) | Survivors (N = 42) | Non-survivors (N = 54) | P value |
| Age, yr | 67 (0–97) | 54 (0–97) | 72 (35–90) | <0.001 |
| Male/female gender, No | 42/54 | 20/21 | 22/33 | = 0.50 |
| Cell count, total | 149 (1–13870) | 105 (2–2410) | 196 (1–13870) | = 0.097 |
| Cell count, %polymorphnuclear | 90 (40–100) (N = 46) | 86 (40–100) (N = 19) | 90 (50–100) (N = 27) | = 0.47 |
| S-glucose, mmol/l | 7.6 (5–35) (N = 36) | 6.9 (5–11) (N = 15) | 8.4 (6–35) (N = 21) | = 0.048 |
| CRP, mg/l | 245 (25–459) (N = 32) | 258 (25–392) (N = 15) | 222 (138–459) (N = 17) | = 0.48 |
| Initial treatment, No | ||||
| Relevant | 34 | 16 | 18 | |
| Irrelevant | 53 | 20 | 33 | = 0.27 |
| Pitt score≥4, No | 56 | 16 | 40 | = 0.006 |
| Other secundary focus, No | 57 | 28 | 29 | = 0.35 |
| Intra-veneous drug use, No | 12 | 9 | 3 | = 0.028 |
| Comorbidity, No | ||||
| None | 26 | 5 | 21 | |
| 1 | 36 | 24 | 12 | |
| >1 | 35 | 26 | 9 | <0.001 |
Unless otherwise indicated, data are presented as No. or median (range).
Initial antibiotic treatment in S. aureus meningitis.
| Antibiotics | Number, total | Number of deaths |
| Ampicillin | 4 | 2 |
| Ampicillin+gentamicin | 12 | 5 |
| Erythromycin | 1 | 1 |
| Penicillin | 32 | 22 |
| Penicillin+gentamicin | 3 | 2 |
| Ampicillin+cefotaxim* | 1 | 1 |
| Mortality in the group | 62% | |
| Methicilline | 3 | 1 |
| Methicilline+fusidic acid | 2 | 1 |
| Dicloxacillin | 4 | 0 |
| Dicloxacillin+rifampin | 1 | 1 |
| Dicloxacillin+fusidic acid | 1 | 0 |
| Ceftriaxone | 12 | 5 |
| Vancomycin+ceftriaxone | 1 | 1 |
| Vancomycin+fusidic acid | 1 | 1 |
| Cefuroxime | 3 | 3 |
| Ampicillin** | 3 | 3 |
| Ampicillin+chloramphenicol** | 1 | 0 |
| Penicillin** | 2 | 2 |
| Mortality in the group | 5% | |
| Total, No. | 87 | 51 |
* MRSA strain. ** Penicillin sensitive strains. Mortality between the two groups is not significantly different (P > 0,2).
Uni- and multivariate analysis of risk factors associated with in-hospital death from S aureus meningitis.
| Univariate HR (95% CI) | Multivariate HR (95% CI) | p value (Multivariate) | |
| 2.65 (1.47–4.78) | 1.57 (0.79–3.13) | 0.20 | |
| 5.13 (2.03–12.96) | 3.45 (1.15–10.30) | 0.03 | |
| 0.31 (0.10–0.99) | 0.64 (0.16–2.53) | 0.53 | |
| 2.58 (1.37–4.93) | 2.14 (1.09–4.19) | 0.03 |
HR: hazard ratio. CI: confidence interval. Cox regression with all variables foced into the model. HRs are adjusted with all variables including in the model.